Convalescent plasma in patients receiving rituximab or ocrelizumab for multiple sclerosis or neuromyelitis Optica spectrum disorder with Covid-19: A multicenter retrospective study

IF 4.8 2区医学 Q1 INFECTIOUS DISEASES

International Journal of Infectious Diseases Pub Date : 2025-02-01 DOI:10.1016/j.ijid.2024.107323

Tanguy Dequidt , Quentin Richier , Céline Louapre , Florence Ader , Yanis Merad , Nicolas Lauwerier , Christine Jacomet , Michel Carles , Charlotte Biron , Vincent Gendrin , Clément Marlat , François Danion , Tristan M Lepage , Albert Sotto , Loïc Bourdellon , Alexandre Mania , Martin Martinot , Georges Le Falher , Alexis Ferre , Benoit Pilmis , Guillaume Martin-Blondel

{"title":"Convalescent plasma in patients receiving rituximab or ocrelizumab for multiple sclerosis or neuromyelitis Optica spectrum disorder with Covid-19: A multicenter retrospective study","authors":"Tanguy Dequidt , Quentin Richier , Céline Louapre , Florence Ader , Yanis Merad , Nicolas Lauwerier , Christine Jacomet , Michel Carles , Charlotte Biron , Vincent Gendrin , Clément Marlat , François Danion , Tristan M Lepage , Albert Sotto , Loïc Bourdellon , Alexandre Mania , Martin Martinot , Georges Le Falher , Alexis Ferre , Benoit Pilmis , Guillaume Martin-Blondel","doi":"10.1016/j.ijid.2024.107323","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Despite vaccination, patients receiving anti-CD20 monoclonal antibodies (mAbs) for multiple sclerosis (MS) or neuromyelitis optica spectrum disorders (NMOSD) have an increased risk of developing severe or protracted COVID-19. The aim of this study was to describe the effect of COVID-19 convalescent plasma (CCP) in patients with MS or NMOSD exposed to anti-CD20 and infected by SARS-CoV-2.</div></div><div><h3>Methods</h3><div>This French national, retrospective cohort study was conducted between November 2020 and June 2023. Patients with MS or NMOSD, under anti-CD20 mAbs, with symptomatic COVID-19 and treated by CCP were screened. Protracted COVID-19 was defined by a duration of symptoms >21 days. The primary endpoint was the overall survival 30 days after CCP administration.</div></div><div><h3>Results</h3><div>Ninety-two patients from 34 hospitals were included, 84 (91%) with MS and 8 (9%) with NMOSD. Overall, 30-day survival was 97% (IC95%: 91-99). SARS-CoV-2 viremia was positive in 47/75 (61%) patients before CCP <em>versus</em> 9/59 (15%) seven days post-CCP. In the 52 patients (57%) with protracted COVID-19, the duration of symptoms before CCP was 51 [28-69] days, including fever in 75% of cases, which disappeared in 100% of patients 7 days post-CCP.</div></div><div><h3>Conclusions</h3><div>CCP could be a therapeutic option in patients exposed to anti-CD20 mAbs for inflammatory demyelinating disease, particularly in those with protracted COVID-19.</div></div>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":"151 ","pages":"Article 107323"},"PeriodicalIF":4.8000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1201971224003989","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Despite vaccination, patients receiving anti-CD20 monoclonal antibodies (mAbs) for multiple sclerosis (MS) or neuromyelitis optica spectrum disorders (NMOSD) have an increased risk of developing severe or protracted COVID-19. The aim of this study was to describe the effect of COVID-19 convalescent plasma (CCP) in patients with MS or NMOSD exposed to anti-CD20 and infected by SARS-CoV-2.

Methods

This French national, retrospective cohort study was conducted between November 2020 and June 2023. Patients with MS or NMOSD, under anti-CD20 mAbs, with symptomatic COVID-19 and treated by CCP were screened. Protracted COVID-19 was defined by a duration of symptoms >21 days. The primary endpoint was the overall survival 30 days after CCP administration.

Results

Ninety-two patients from 34 hospitals were included, 84 (91%) with MS and 8 (9%) with NMOSD. Overall, 30-day survival was 97% (IC95%: 91-99). SARS-CoV-2 viremia was positive in 47/75 (61%) patients before CCP versus 9/59 (15%) seven days post-CCP. In the 52 patients (57%) with protracted COVID-19, the duration of symptoms before CCP was 51 [28-69] days, including fever in 75% of cases, which disappeared in 100% of patients 7 days post-CCP.

Conclusions

CCP could be a therapeutic option in patients exposed to anti-CD20 mAbs for inflammatory demyelinating disease, particularly in those with protracted COVID-19.

查看原文本刊更多论文

接受利妥昔单抗或奥克雷单抗治疗多发性硬化症或视神经脊髓炎伴COVID-19患者的恢复期血浆：一项多中心回顾性研究

背景：尽管接种了疫苗，但接受抗cd20单克隆抗体（mab）治疗多发性硬化症（MS）或视神经脊髓炎谱系障碍（NMOSD）的患者发展为严重或长期COVID-19的风险增加。本研究的目的是描述COVID-19恢复期血浆（CCP）对暴露于抗cd20并感染SARS-CoV-2的MS或NMOSD患者的影响。方法：这项法国全国性的回顾性队列研究于2020年11月至2023年6月进行。筛选抗cd20单抗下伴有症状性COVID-19并接受CCP治疗的MS或NMOSD患者。延长型COVID-19的定义是症状持续时间超过21天。主要终点是给药后30天的总生存期。结果：纳入34家医院92例患者，其中MS 84例（91%），NMOSD 8例（9%）。总体而言，30天生存率为97% （IC95%: 91-99）。CCP前47/75（61%）患者的SARS-CoV-2病毒血症呈阳性，CCP后7天为9/59（15%）。52例（57%）延期性COVID-19患者，CCP前症状持续时间为51[28-69]天，其中75%的患者发热，CCP后7天100%的患者发热消失。结论：对于暴露于抗cd20单抗的炎症性脱髓鞘疾病患者，CCP可能是一种治疗选择，特别是对于那些延长的COVID-19患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Infectious Diseases 医学-传染病学

CiteScore

18.90

自引率

2.40%

发文量

1020

审稿时长

30 days

期刊介绍： International Journal of Infectious Diseases (IJID) Publisher: International Society for Infectious Diseases Publication Frequency: Monthly Type: Peer-reviewed, Open Access Scope: Publishes original clinical and laboratory-based research. Reports clinical trials, reviews, and some case reports. Focuses on epidemiology, clinical diagnosis, treatment, and control of infectious diseases. Emphasizes diseases common in under-resourced countries.